Download PDF
Semin Liver Dis 2003; 23(1): 059-068
DOI: 10.1055/s-2003-37585
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatitis B in Children

Annemarie L. Broderick1 , Maureen M. Jonas2
  • 1Fellow in Gastroenterology and Nutrition, Division of Gastroenterology, Department of Medicine
  • 2Division of Gastroenterology, Department of Medicine, Children's Hospital, Boston, Massachusetts
Further Information

Publication History

Publication Date:
03 March 2003 (online)

    Permissions and Reprints

ABSTRACT

Childhood hepatitis B virus (HBV) infection presents both medical and public health challenges. Infants who acquire HBV perinatally have up to 90% risk of developing chronic HBV infection. Many HBV-infected children have normal alanine aminotransferase values and minimal chronic hepatitis. Children with chronic HBV infection are usually asymptomatic but may develop chronic liver disease or hepatocellular carcinoma. Both interferon-alfa and lamivudine are available for the treatment of chronic hepatitis B in children, but the optimal treatment of children with chronic HBV infection is evolving as the indications, timing, efficacy, and side effects of the treatments are better understood. Universal infant vaccination has been shown to decrease the frequency of HBV infection and its sequelae. This article addresses aspects of HBV infection that are either unique to or different in children.

KEYWORDS

Hepatitis B - infants - children - perinatal - vaccination - treatment

REFERENCES

  • 1 Anonymous. Achievements in Public Health: hepatitis B vaccination-United States, 1982-2002.  MMWR Morb Mortal Wkly Rep . 2002;  51 549-552
    PubMedSearch in Google Scholar
  • 2 McQuillan G M, Coleman P J, Kruszon-Moran D. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.  Am J Public Health . 1999;  89 14-18
    PubMedSearch in Google Scholar
  • 3 Goldstein S T, Alter M J, Williams I T. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998; implications for vaccination programs.  J Infect Dis . 2002;  185 713-719
    CrossrefPubMedSearch in Google Scholar
  • 4 Hsu H Y, Chang M H, Chen D S, Lee C Y, Sung J L. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984; a study just before mass hepatitis B vaccination program in Taiwan.  J Med Virol . 1986;  18 301-307
    PubMedSearch in Google Scholar
  • 5 Ni Y H, Chang M H, Huang L M. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination.  Ann Intern Med . 2001;  135 796-800
    PubMedSearch in Google Scholar
  • 6 Barr D, Hershow R, Furner S, Handler A, Levy P. Assessing prenatal hepatitis B screening in Illinois with an inexpensive study design adaptable to other jurisdictions.  Am J Public Health . 1999;  89 19-24
    PubMedSearch in Google Scholar
  • 7 Shiraki K. Toward control of hepatitis B in the Asia-Pacific region.  J Gastroenterol Hepatol . 2000;  15 E11-E15
    CrossrefPubMedSearch in Google Scholar
  • 8 Lee S-D, Tsai Y-T, Wu T-C. Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus.  Lancet . 1988;  2 833-834
    PubMedSearch in Google Scholar
  • 9 Beasley R P, Stevens C E, Shiao I S, Meng H C. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B.  Lancet . 1975;  2 740-741
    PubMedSearch in Google Scholar
  • 10 Pickering L. 2000 Red Book: Report of the Committee of Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics 2000: 98-101
    Search in Google Scholar
  • 11 Lok A S. Hepatitis B infection: pathogenesis and management.  J Hepatol . 2000;  32 89-97
    PubMedSearch in Google Scholar
  • 12 Chu C M, Liaw Y F. Natural history of chronic hepatitis B virus infection: an immunopathological study.  J Gastroenterol Hepatol . 1997;  12 S218-S222
    PubMedSearch in Google Scholar
  • 13 Rehermann B, Lau D, Hoofnagle J H, Chisari F V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.  J Clin Invest . 1996;  97 1655-1665
    PubMedSearch in Google Scholar
  • 14 Shiraki K, Yoshihara N, Sakurai M, Eto T, Kawana T. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen.  J Pediatr . 1980;  97 768-770
    PubMedSearch in Google Scholar
  • 15 Kao J H, Hsu H M, Shau W Y, Chang M H, Chen D S. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan.  J Pediatr . 2001;  139 349-352
    CrossrefPubMedSearch in Google Scholar
  • 16 Cacciola I, Cerenzia G, Pollicino T. Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.  J Hepatol . 2002;  36 426-432
    CrossrefPubMedSearch in Google Scholar
  • 17 Kleinknecht C, Levy M, Peix A. Membranous glomerulonephritis and hepatitis B surface antigen in children.  J Pediatr . 1979;  95 946-952
    PubMedSearch in Google Scholar
  • 18 Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy.  J Pediatr . 1985;  106 571-578
    PubMedSearch in Google Scholar
  • 19 Lok A SF, Lai C L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children.  Hepatology . 1988;  8 1130-1133
    CrossrefPubMedSearch in Google Scholar
  • 20 Lok A SF, Lai C L, Su P C. Treatment of chronic hepatitis B with interferon: experience in Asian patients.  Semin Liver Dis . 1989;  9 249-253
    PubMedSearch in Google Scholar
  • 21 Hsu H-Y, Chang M-H, Lee C-Y. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection.  Hepatology . 1992;  15 382-386
    PubMedSearch in Google Scholar
  • 22 Bortolotti F, Cadrobbi P, Crivellaro C. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood.  Gastroenterology . 1990;  99 805-810
    PubMedSearch in Google Scholar
  • 23 Chen P J, Chen D S. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives.  Semin Liver Dis . 1999;  19 253-262
    PubMedSearch in Google Scholar
  • 24 McMahon B J, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.  Ann Intern Med . 2001;  135 759-768
    CrossrefPubMedSearch in Google Scholar
  • 25 Tanaka T, Miyamoto H, Hino O. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy.  Hum Pathol . 1986;  17 202-204
    PubMedSearch in Google Scholar
  • 26 Cheah P L, Looi L M, Lin H P, Yap S F. Childhood primary hepatocellular carcinoma and hepatitis B virus infection.  Cancer . 1990;  65 174-176
    PubMedSearch in Google Scholar
  • 27 Giacchino R, Navone C, Facco F. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases.  Dig Dis Sci . 1991;  36 1143-1146
    CrossrefPubMedSearch in Google Scholar
  • 28 Pontisso P, Basso G, Perilongo G. Does hepatitis B virus play a role in primary liver cancer in children of Western countries?.  Cancer Detect Prev . 1991;  15 363-368
    PubMedSearch in Google Scholar
  • 29 Hsu H C, Wu M Z, Chang M H, Su I J, Chen D S. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis.  J Hepatol . 1987;  5 260-267
    CrossrefPubMedSearch in Google Scholar
  • 30 Chang M H, Chen C J, Lai M S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.  N Engl J Med . 1997;  336 1906-1907
    CrossrefPubMedSearch in Google Scholar
  • 31 Ruíz-Moreno M, Rua M J, Molina J. Prospective, randomized trial of interferon-alpha in children with chronic hepatitis B.  Hepatology . 1991;  13 1035-1039
    CrossrefPubMedSearch in Google Scholar
  • 32 Barbera C, Bortoletti F, Crivellaro C. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.  Hepatology . 1994;  20 287-290
    CrossrefPubMedSearch in Google Scholar
  • 33 Narkewicz M R, Smith D, Silverman A. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment.  J Pediatr . 1995;  127 815-818
    PubMedSearch in Google Scholar
  • 34 Vajro P, Tedesco M, Fontanella A. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection.  Pediatr Infect Dis J . 1996;  15 223-231
    CrossrefPubMedSearch in Google Scholar
  • 35 Sokal E M, Conjeevaram H S, Roberts E A. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.  Gastroenterology . 1998;  114 988-995
    PubMedSearch in Google Scholar
  • 36 Lai C L, Lok A S, Lin H J. Placebo-controlled trial of recombinant alpha2-interferon in Chinese HBsAg-carrier children.  Lancet . 1987;  2 877-880
    PubMedSearch in Google Scholar
  • 37 Lai C L, Lin H J, Lau J N. Effect of recombinant alpha2 interferon with or without prednisone in Chinese HBsAg carrier children.  Q J Med . 1991;  78 155-163
    PubMedSearch in Google Scholar
  • 38 Sokal E M. Viral hepatitis throughout infancy to adulthood.  Acta Gastroenterol Belg . 1998;  61 170-174
    PubMedSearch in Google Scholar
  • 39 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B.  Liver . 1995;  15 143-148
    PubMedSearch in Google Scholar
  • 40 Gurakan F, Kocak N, Ozen H, Yuce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection.  Pediatr Infect Dis J . 2000;  19 52-56
    CrossrefPubMedSearch in Google Scholar
  • 41 Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis.  Clin Infect Dis . 1996;  23 131-137
    PubMedSearch in Google Scholar
  • 42 Korenman J, Baker B, Waggoner J. Long-term remission of chronic hepatitis B after alpha-interferon therapy.  Ann Intern Med . 1991;  114 629-634
    PubMedSearch in Google Scholar
  • 43 Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology . 1999;  29 971-975
    CrossrefPubMedSearch in Google Scholar
  • 44 Kocak N, Gurakan F, Saltik I N, Ozen H, Yuce A. Long term prognosis of interferon nonresponder children with hepatitis B.  Am J Gastroenterol . 2000;  95 1841
    PubMedSearch in Google Scholar
  • 45 Ruíz-Moreno M, Fernández P, Leal A. Pilot interferon-β trial in children with chronic hepatitis B who had previously not responded to interferon-alfa therapy.  Pediatrics . 1997;  99 222-225
    CrossrefPubMedSearch in Google Scholar
  • 46 Ballauff A, Schneider T, Gerner P. Safety and efficacy of interferon retreatment in children with chronic hepatitis B.  Eur J Pediatr . 1998;  157 382-385
    CrossrefPubMedSearch in Google Scholar
  • 47 Iorio R, Pensati P, Botta S. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis.  Pediatr Infect Dis J . 1997;  16 984-990
    CrossrefPubMedSearch in Google Scholar
  • 48 Gottrand F, Michaud L, Guimber D. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis.  Eur J Pediatr . 1996;  155 1031-1034
    CrossrefPubMedSearch in Google Scholar
  • 49 Comanor L, Minor J, Conjeevaram H S. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children.  J Viral Hepat . 2001;  8 139-147
    CrossrefPubMedSearch in Google Scholar
  • 50 Lai C-L, Chien R-N, Leung N WY. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
    CrossrefPubMedSearch in Google Scholar
  • 51 Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med . 1999;  341 1256-1263
    CrossrefPubMedSearch in Google Scholar
  • 52 Liaw Y-F, Leung N WY, Chang T-T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.  Gastroenterology . 2000;  119 172-180
    CrossrefPubMedSearch in Google Scholar
  • 53 Leung N W, Lai C L, Chang T T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology . 2001;  33 1527-1532
    CrossrefPubMedSearch in Google Scholar
  • 54 Jonas M M, Kelley D A, Mizerski J. Clinical trial of lamivudine in children with chronic hepatitis B.  N Engl J Med . 2002;  346 1706-1713
    CrossrefPubMedSearch in Google Scholar
  • 55 Dikici B, Bosnak M, Kara I H. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection.  Pediatr Infect Dis J . 2001;  20 988-992
    PubMedSearch in Google Scholar
  • 56 Smith N, Yusuf H, Averhoff F. Surveillance and prevention of hepatitis B virus transmission.  Am J Public Health . 1999;  89 11-13
    PubMedSearch in Google Scholar
  • 57 Yuen M F, Lim W L, Cheng C C, Lam S K, Lai C L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children.  Hepatology . 1999;  29 924-927
    CrossrefPubMedSearch in Google Scholar
  • 58 Szmuness W, Stevens C E, Harley E J. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.  N Engl J Med . 1980;  303 833-841
    PubMedSearch in Google Scholar
  • 59 Anonymous. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Morb Mortal Wkly Rep . 1996;  45 1-35
    PubMedSearch in Google Scholar
  • 60 Ascherio A, Zhang S M, Hernan M A. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med . 2001;  344 327-332
    CrossrefPubMedSearch in Google Scholar
  • 61 Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.  N Engl J Med . 2001;  344 319-326
    CrossrefPubMedSearch in Google Scholar
  • 62 Giacchino R, Main J, Timitilli A. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B.  Liver . 1995;  15 143-148
    PubMedSearch in Google Scholar